Jim and Jeff discuss Eli Lilly after the company beat on quarterly profit and hiked its full-year guidance on strong sales of Mounjaro and Zepbound. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake
CNBC Investing Club Disclaimer
Jim and Jeff discuss Eli Lilly after the company beat on quarterly profit and hiked its full-year guidance on strong sales of Mounjaro and Zepbound. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake
CNBC Investing Club Disclaimer